Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer

American Journal of Clinical Pathology

Volumn 138, Issue 4, 2012, Pages 535-544

  Rahman, Mohammed Tanjimur ^a   Nakayama, Kentaro ^a   Rahman, Munmun ^a   Katagiri, Hiroshi ^a   Katagiri, Atsuko ^a   Ishibashi, Tomoka ^a   Ishikawa, Masako ^a   Iida, Kouji ^a   Nakayama, Satoru ^b   Otsuki, Yoshiro ^b   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

Author keywords

Secretase inhibitor; Chemoresistance; NICD3; Notch3; Outcome; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GAMMA SECRETASE INHIBITOR; NOTCH3 RECEPTOR; PACLITAXEL; SMALL INTERFERING RNA;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTORS, NOTCH; RETROSPECTIVE STUDIES; RNA, SMALL INTERFERING; SURVIVAL RATE;

EID: 84866982852     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPKDLRQ8F3EWNS     Document Type: Article

References (21)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995;45:8-30.
2. Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol.2009;4:287-313.
3. Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol. 2006;32:875-886. (Pubitemid 44469301)
4. Park JT, Li M, Nakayama K, et al. Notch3 gene amplification in ovarian cancer. Cancer Res. 2006;66:6312-6318.
5. Konishi J, Kawaguchi KS, Vo H, et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res.2007;67:8051-8057. (Pubitemid 47395139)
6. Yamaguchi N, Oyama T, Ito E, et al. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res.2008;68:1881-1888. (Pubitemid 351416574)
7. Gallahan D, Callahan R. The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4). Oncogene. 1997;14:1883-1890. (Pubitemid 27217801)
8. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006;6:347-359.
9. Park JT, Chen X, Trope CG, et al. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol. 2010;177:1087-1094.
10. Yeasmin S, Nakayama K, Rahman MT, et al. Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecol Oncol.2010;117:409-416.
11. Yamamoto K, Kikuchi Y, Kudoh K, et al. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol. 2000;126:168-172. (Pubitemid 30140217)
12. Curry CL, Reed LL, Golde TE, et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene. 2005;24:6333-6344. (Pubitemid 41486467)
13. van Es JH, van Gijn ME, Riccio O, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435:959-963. (Pubitemid 40896322)
14. Berek JS, Martinez-Maza O. Molecular and biologic factors in the pathogenesis of ovarian cancer. J Reprod Med.1994;39:241-248. (Pubitemid 24125862)
15. Diaz-Montes TP, Bristow RE. Secondary cytoreduction for patients with recurrent ovarian cancer. Curr Oncol Rep.2005;7:451-458. (Pubitemid 41684231)
16. Jung SG, Kwon YD, Song JA, et al. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma. Cancer Sci. 2010;101:1977-1983.
17. Harter P, du Bois A. The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr Opin Oncol. 2005;17:505-514. (Pubitemid 41224935)
18. Gadducci A, Iacconi P, Cosio S, et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol.2000;79:344-349.
19. Gadducci A, Iacconi P, Fanucchi A, et al. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer. Anticancer Res. 2000;20:1959-1964. (Pubitemid 30636165)
20. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100:1152-1161. (Pubitemid 38325942)
21. Weinstein IB, Joe A. Oncogene addiction. Cancer Res.2008;68:3077-3080; discussion 3080.